Cefiderocol for resistant Gram negatives: linking in vitro activity with clinical effectiveness

Clin Microbiol Infect. 2024 Feb;30(2):155-158. doi: 10.1016/j.cmi.2023.11.012. Epub 2023 Nov 28.

Authors

Fabian Patauner¹, Emanuele Durante-Mangoni²

Affiliations

¹ Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy; Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Ospedale Monaldi, Naples, Italy.
² Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy; Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Ospedale Monaldi, Naples, Italy. Electronic address: emanuele.durante@unicampania.it.

PMID: 38036218
DOI: 10.1016/j.cmi.2023.11.012

No abstract available

Publication types

Editorial

MeSH terms

Anti-Bacterial Agents* / pharmacology
Anti-Bacterial Agents* / therapeutic use
Cefiderocol*
Cephalosporins / pharmacology
Drug Resistance, Multiple, Bacterial
Gram-Negative Bacteria
Humans
Microbial Sensitivity Tests
Treatment Outcome

Substances

Cefiderocol
Anti-Bacterial Agents
Cephalosporins